The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
Grandori, C., Cowley, S. M., James, L. P., & Eisenman, R. N. (2000) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.16.1.653 · Cited by 1,333
Transposition and amplification of oncogene-related sequences in human neuroblastomas
Kohl, N. E., Kanda, N., Schreck, R. R., Bruns, G., Latt, S. A., Gilbert, F., & Alt, F. W. (1983) · Cell · doi:10.1016/0092-8674(83)90169-1 · Cited by 731
SDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma
Hao, H.-X., Khalimonchuk, O., Schraders, M., Dephoure, N., Bayley, J.-P., Kunst, H., Devilee, P., Cremers, C. W. R. J., Schiffman, J. D., Bentz, B. G., et al. (2009) · Science · doi:10.1126/science.1175689 · Cited by 702 · cited 1×
“861" language="eng" relation="no"> Hereditary pheochromocytoma (PCC) is often caused by germline mutations in one of nine susceptibility genes described to dat”
BackgroundSDHA is a tumor suppressor gene causing paraganglioma
Burnichon, N., Brière, J.-J., Libé, R., Vescovo, L., Rivière, J., Tissier, F., Jouanno, E., Jeunemaitre, X., Bénit, P., Tzagoloff, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq206 · Cited by 650
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Nair, S. K., & Burley, S. K. (2003) · Cell · doi:10.1016/s0092-8674(02)01284-9 · Cited by 551
Cited by
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Pheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
Realizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 624
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Dahia, P. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3648 · Cited by 545
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
Favier, J., Amar, L., & Gimenez-Roqueplo, A.-P. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.188 · Cited by 490
Human Genome Sequencing in Health and Disease
Gonzaga-Jauregui, C., Lupski, J. R., & Gibbs, R. A. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-051010-162644 · Cited by 473
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431
“…critical for its transforming potential in cell culture assays, recurrent shallow deletions of MAX were observed in some cancers, particularly pheochromocytomas and gastrointestinal stromal tumors (Burnichon et al., 2012; Comino-Me´ndez et al., 2011; Pantaleo et al., 2017; Schaefer et al., 2017).”
Self-citationNext-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification
Kamps, R., Brandão, R., Bosch, B., Paulussen, A., Xanthoulea, S., Blok, M., & Romano, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020308 · Cited by 453
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
Welander, J., Söderkvist, P., & Gimm, O. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0170 · Cited by 355
LaDuca, H., Stuenkel, A. J., Dolinsky, J. S., Keiles, S., Tandy, S., Pesaran, T., Chen, E., Gau, C.-L., Palmaer, E., Shoaepour, K., et al. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.40 · Cited by 332
MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
Burnichon, N., Cascón, A., Schiavi, F., Morales, N. P., Comino-Méndez, I., Abermil, N., Inglada-Pérez, L., de Cubas, A. A., Amar, L., Barontini, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0160 · Cited by 331
Self-citationIntegrated genomic characterization of IDH1-mutant glioma malignant progression
Bai, H., Harmancı, A. S., Erson-Omay, E. Z., Li, J., Coşkun, S., Simon, M., Krischek, B., Özduman, K., Omay, S. B., Sorensen, E. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3457 · Cited by 329
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
Hamidi, O., Young, W. F., Iñiguez-Ariza, N. M., Kittah, N. E., Gruber, L., Bancos, C., Tamhane, S., & Bancos, I. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00992 · Cited by 316
The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis
Carroll, P. A., Freie, B. W., Mathsyaraja, H., & Eisenman, R. N. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0650-z · Cited by 289
Integrative genomic and transcriptomic analysis of leiomyosarcoma
Chudasama, P., Mughal, S. S., Sanders, M. A., Hübschmann, D., Chung, I., Deeg, K. I., Wong, S.-H., Rabe, S., Hlevnjak, M., Zapatka, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02602-0 · Cited by 306
Ripperger, T., Bielack, S. S., Borkhardt, A., Brecht, I. B., Burkhardt, B., Calaminus, G., Debatin, K., Deubzer, H., Dirksen, U., Eckert, C., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38142 · Cited by 283
Rednam, S. P., Erez, A., Druker, H., Janeway, K. A., Kamihara, J., Kohlmann, W. K., Nathanson, K. L., States, L. J., Tomlinson, G. E., Villani, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0547 · Cited by 280
The NGS in PPGL (NGSnPPGL) Study Group, Toledo, R. A., Burnichon, N., Cascon, A., Benn, D. E., Bayley, J.-P., Welander, J., Tops, C. M., Firth, H., Dwight, T., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.185 · Cited by 275
Self-citationSuccinate dehydrogenase (SDH)‐deficient neoplasia
Gill, A. J. (2018) · Histopathology · doi:10.1111/his.13277 · Cited by 256
Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia
Gill, A. J. (2012) · Pathology · doi:10.1097/pat.0b013e3283539932 · Cited by 215
Comino-Méndez, I., de Cubas, A. A., Bernal, C., Álvarez-Escolá, C., Sánchez-Malo, C., Ramírez-Tortosa, C. L., Pedrinaci, S., Rapizzi, E., Ercolino, T., Bernini, G., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt069 · Cited by 169
Self-citationMax deletion destabilizes MYC protein and abrogates Eµ- Myc lymphomagenesis
Mathsyaraja, H., Freie, B., Cheng, P.-F., Babaeva, E., Catchpole, J. T., Janssens, D., Henikoff, S., & Eisenman, R. N. (2019) · Genes & Development · doi:10.1101/gad.325878.119 · Cited by 54
Richter, S., Qin, N., Pacak, K., & Eisenhofer, G. (2013) · Advances in Pharmacology · doi:10.1016/b978-0-12-411512-5.00014-2 · Cited by 42
Kamilaris, C. D. C., & Stratakis, C. A. (2018) · HORMONES · doi:10.1007/s42000-018-0072-y · Cited by 7
Metadata
- Authors
- Comino-Méndez, I., Gracia-Aznárez, F. J., Schiavi, F., Landa, I., Leandro-García, L. J., Letón, R., Honrado, E., Ramos-Medina, R., Caronia, D., Pita, G., Gómez-Graña, Á., de Cubas, A. A., Inglada-Pérez, L., Maliszewska, A., Taschin, E., Bobisse, S., Pica, G., Loli, P., Hernández-Lavado, R., Díaz, J. A., Gómez-Morales, M., González-Neira, A., Roncador, G., Rodríguez-Antona, C., Benítez, J., Mannelli, M., Opocher, G., Robledo, M., & Cascón, A.
- Venue
- Nature Genetics
- Published
- 2011-06-19
- Volume
- 43
- Issue
- 7
- Pages
- 663-667
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1966955143
- Cited by
- 526
- References
- 35
- FWCI
- 54.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.